Get the Stockscreener App
28.63
4.37%
1.20
After Hours:
28.82
0.19
+0.66%
Alkermes Plc stock is traded at $28.63, with a volume of 1.31M.
It is up +4.37% in the last 24 hours and down -5.45% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$27.43
Open:
$27.64
24h Volume:
1.31M
Relative Volume:
0.76
Market Cap:
$4.73B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
14.68
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
+7.83%
1M Performance:
-5.45%
6M Performance:
-20.47%
1Y Performance:
+8.32%
1-Day Range:
$27.51
$28.73
1-Week Range:
$26.07
$28.73
52-Week Range:
$25.56
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.63 | 4.53B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Live Scanner Shows Breakout on Alkermes plcMarket Surge Signal for Swing Traders Triggered - metal.it
Is Alkermes plc in a long term uptrendWealth Leverage Stock List - mustnews.co.kr
BlackRock increases stake in Alkermes to 17% - Investing.com India
BlackRock increases stake in Alkermes to 17% By Investing.com - Investing.com Nigeria
Alkermes plc Included in Top Momentum ScanInvestment Strategy Designed for Capital Protection - metal.it
Chondrosarcoma Market: Epidemiology, Pipeline Products, - openPR.com
Alkermes plc Announces Pricing of New Term Loans - AOL.com
What markets is AAON Inc. expanding into Is Alkermes plc stock a good long term investment optionBuild a diversified portfolio for steady growth - Jammu Links News
What is the dividend policy of Alkermes plc stockUnmatched market gains - Jammu Links News
Is Alkermes plc a growth stock or a value stockInvest smarter with expert trading signals - Jammu Links News
What makes Alkermes plc stock price move sharplyInvest confidently with professional advice - Jammu Links News
Is Alkermes plc stock overvalued or undervaluedGet exclusive access to expert stock recommendations - Jammu Links News
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - MSN
What catalysts could drive Alkermes plc stock higher in 2025Invest confidently with professional advice - Jammu Links News
Should I hold or sell Alkermes plc stock in 2025Get expert analysis on top stock picks - Jammu Links News
Needham & Company LLC Reaffirms "Buy" Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
How does Alkermes plc generate profit in a changing economyBuild capital through low-risk investments - Jammu Links News
What are analysts’ price targets for Alkermes plc in the next 12 monthsAchieve rapid portfolio growth with expert guidance - Jammu Links News
What are the technical indicators suggesting about Alkermes plcDiscover investment plans that deliver results - Jammu Links News
How strong is Alkermes plc company’s balance sheetUnlock powerful portfolio optimization tools - Jammu Links News
What markets is Alkermes plc expanding into Is ASLE stock a good long term investment optionBuild a portfolio that outperforms consistently - Jammu Links News
Alkermes Reports Q2 2025 Financial Results, Reiterates Expectations and Highlights Positive Clinical Study Results - AInvest
ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Alkermes shares climb 5% following Q2 earnings and revenue beat - MSN
(07/31/25) ALKS: Positive Narcolepsy Drug Trial Puts this Biotech Name in F - moneyshow.com
Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances - MSN
Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha
Alkermes stock price target raised to $42 from $40 at RBC Capital - Investing.com Nigeria
Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript - Insider Monkey
Alkermes Beat Expectations With A Strong Second Quarter - Finimize
Schizophrenia Drugs Market Exclusive Report with Detailed - openPR.com
RBC Raises Price Target on Alkermes to $42 From $40, Keeps Sector Perform Rating - MarketScreener
Alkermes PLC (ALKS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Alkermes: Q2 Earnings Snapshot - Norwalk Hour
Alkermes Reports Strong Q2 2025 Financial Results - TipRanks
Trading Bots Trigger Alerts on Alkermes plc ActivityDaily Smart Money Movement Monitor Activated - metal.it
Multi Factor Analysis Ranks Alkermes plc as Strong BuyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alkermes Earnings Call: Strong Growth and Promising Trials - TipRanks
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire
Alkermes price target lowered to $33 from $35 at BofA - TipRanks
Why Alkermes plc stock attracts strong analyst attentionScalable Portfolio Growth Suggestions Released - metal.it
Alkermes Q2 2025 Earnings Call Transcript - MarketBeat
Published on: 2025-07-29 17:34:19 - metal.it
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):